JP4709739B2 - How to improve hair growth - Google Patents
How to improve hair growth Download PDFInfo
- Publication number
- JP4709739B2 JP4709739B2 JP2006501201A JP2006501201A JP4709739B2 JP 4709739 B2 JP4709739 B2 JP 4709739B2 JP 2006501201 A JP2006501201 A JP 2006501201A JP 2006501201 A JP2006501201 A JP 2006501201A JP 4709739 B2 JP4709739 B2 JP 4709739B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- creatine
- hair loss
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
発明の分野
本発明はパーソナルケアの分野に関する。より特定的には、本発明は、毛髪成長の増進および脱毛の予防を行う方法に関する。
The present invention relates to the field of personal care. More specifically, the present invention relates to a method for promoting hair growth and preventing hair loss.
発明の背景
禿頭症を治療および予防する安全で信頼性のある方法を見いだす探究は、長年にわたり進められてきた。確かに命にかかわるものではないが、脱毛は、男性および女性のいずれにおいても、罹患者にかなりの苦痛を引き起こし、個人の自尊心に重大な影響を及ぼす可能性がある。安全かつ有効な治療法を見いだすうえで問題となる点は多い。第1に、脱毛の根本的な原因は、個人差があって必ずしも同じであるとは限らない。また、毛髪が成長する過程にはいくつかの時期が含まれ、正常な盛んな毛髪の成長を変化させる可能性のある寄与因子は多数存在する。毛髪成長周期は、3つの時期:成長期(毛嚢できわめて高レベルの細胞増殖が起こって毛髪が活発に成長する);退行期(発毛を可能にする毛嚢の増殖活性が一時的に低下する);および休止期(毛が抜け落ちて新しい成長期が開始されるまで、毛嚢は単純に成長を停止して退行する)に分けられる。
BACKGROUND OF THE INVENTION The search for finding safe and reliable methods for treating and preventing baldness has been underway for many years. While certainly not life-threatening, hair loss can cause significant distress to affected individuals and can have a significant impact on individual self-esteem in both men and women. There are many problems in finding a safe and effective treatment. First, the root cause of hair loss is not necessarily the same because of individual differences. Also, the process of hair growth involves several periods, and there are many contributing factors that can change the growth of normal and active hair. The hair growth cycle is divided into three phases: the growth phase (the hair follicles undergo very high levels of cell proliferation and the hair grows actively); the regression phase (the hair follicle's proliferative activity that enables hair growth is temporarily And the resting phase (the hair follicles simply stop growing and regress until the hair falls off and a new growth phase begins).
もちろん、平均的な人が日常的に多くの毛髪を失うことはまったく正常なことであるので、この周期は、通常、失われた毛髪を補充すべく生涯を通じて継続的に反復される。しかしながら、周期は、何人たりとも加齢に伴って遅くなり、正常な毛髪は、次第に細くなる毛髪(うぶ毛)と徐々に入れ替わり、そして周期数は、不足するようになる。異常な脱毛を患う人の場合、過程の異常な加速であろうと他の変化であろうと、正常な周期過程が何らかの形で破壊されることは明らかであり;この結果、いずれは、休止期への移行が一段と速まって、さらには、次第により多くのうぶ毛が生えるようになり、最終的には、禿頭症になる可能性がある。 Of course, since it is quite normal for the average person to lose a lot of hair on a daily basis, this cycle is usually repeated continuously throughout life to replace the lost hair. However, the cycle slows with age, normal hair is gradually replaced with gradually thinning hair (faint hair), and the number of cycles becomes deficient. For people with abnormal hair loss, it is clear that the normal cycle process is somehow destroyed, whether it is an abnormal acceleration of the process or other changes; The transition of the skin becomes faster and more and more vellus hair grows, and eventually, baldness may occur.
長続きしなくなる周期へのこの移行の原因は、依然として完全には解明されていない。多数の因子が毛髪成長様式に寄与しており、こうした因子としては、たとえば、食事制限、薬剤暴露、およびホルモンが挙げられるが、これらに限定されるものではない。脱毛を治療するための多種多様な方式が、長年にわたり提案されてきており;これらの治療法では、ホルモンのような有害因子の作用を相殺しようと試みることもあれば、休眠状態の毛嚢の活性を直接再刺激しようと試みることもある。毛髪成長の復活に奏効することが明らかにされている薬剤の多くは、ミノキシジルまたはプロカインのような合成医薬剤である。これらの物質は有効ではあるが、いくつかの欠点を有している。これらの欠点としては、薬剤として、望ましくない全身的作用を有する可能性があることおよび/または経口投与しなければならない可能性があること;多くの場合、治療法は、主にアンドロゲン性脱毛症もしくは男性型禿頭症を対象にしているので、脱毛を患う女性候補者に使用すると安全でなく効果もない可能性があることが挙げられる。したがって、毛髪成長促進剤のゴールドスタンダードは、化学的性質も標的もホルモン性でなく、脱毛を患う男性および女性の両方に心配なく局所投与することができ、しかも好ましくは毛嚢自体の刺激に直接的効果を有する天然物である。ソーパルメットのようないくつかの天然に存在する物質を毛髪成長の促進に使用することが推奨されてきたが、男性および女性の両方の脱毛に対する自然療法として、広に商業的成功を収めているわけでもなければ、なんら容認されているわけでもない。したがって、非ホルモン性の天然に存在する物質を活性成分として利用する脱毛の治療方法の必要性が依然として存在する。本発明は、このたび、そのような方法を提供する。 The cause of this transition to a non-lasting cycle is still not fully understood. A number of factors contribute to hair growth patterns, including but not limited to, dietary restrictions, drug exposure, and hormones. A wide variety of methods for treating hair loss have been proposed for many years; these treatments attempt to counteract the effects of harmful factors such as hormones, or dormant hair follicles. Attempts may be made to directly re-stimulate activity. Many of the drugs that have been shown to be effective in restoring hair growth are synthetic pharmaceutical agents such as minoxidil or procaine. While these materials are effective, they have several drawbacks. These disadvantages include the possibility of having undesired systemic effects as a drug and / or having to be administered orally; in many cases the treatment is mainly androgenic alopecia Or because it is targeted at androgenetic baldness, it may be unsafe and ineffective when used for female candidates suffering from hair loss. Therefore, the gold standard for hair growth promoters is neither chemistry nor target hormonal, can be administered topically to both men and women suffering from hair loss, and preferably directly to the stimulation of the hair follicle itself. It is a natural product with a positive effect. Although some naturally occurring substances such as soap palmet have been recommended for use in promoting hair growth, they have gained widespread commercial success as natural remedies for hair loss in both men and women. But it's not acceptable at all. Thus, there remains a need for a method of treating hair loss that utilizes non-hormonal naturally occurring substances as active ingredients. The present invention now provides such a method.
発明の概要
本発明は、毛嚢刺激有効量のクレアチンまたはクレアチン誘導体を毛嚢に適用することを含む、毛嚢の増殖活性を刺激する方法に関する。本発明はまた、毛嚢刺激有効量のクレアチンまたはクレアチン誘導体を毛髪および/または頭皮に局所適用することを含む、脱毛を治療または予防する方法に関する。したがって、本発明の方法では、天然に存在する物質であるクレアチン(通常、ヒト細胞中に存在する)を利用して、毛嚢の毛髪成長レベルを増大させる。
SUMMARY OF THE INVENTION The present invention relates to a method of stimulating hair follicle proliferative activity comprising applying a hair follicle stimulating effective amount of creatine or a creatine derivative to a hair follicle. The present invention also relates to a method of treating or preventing hair loss comprising topically applying to the hair and / or scalp a hair follicle stimulating effective amount of creatine or a creatine derivative. Thus, the method of the present invention utilizes the naturally occurring substance creatine (usually present in human cells) to increase hair follicle hair growth levels.
発明の詳細な説明
本発明者らは、予想外なことに、クレアチンが、真皮乳頭細胞に適用されたときに、それらの細胞のDNA合成レベルの著しい増大を引き起こしうることを観測した(実施例1参照)。真皮乳頭細胞は、毛嚢中に存在し、ケラチノサイト(マトリックス細胞)の増殖および分化の活性をモジュレートすることにより毛髪成長に関与することが示唆された(Shimaoka et al., J. Dermatol. Sci.7(Suppl): S79-S83, 1994)。したがって、DNA合成の増進が毛髪成長の実際の増進をもたらしうるかを調べようと試みた。この場合にも、予想外なことに、1mM程度の少量でクレアチンを適用することにより、未処置の対照に対して統計的に有為なレベルで毛栓において実際の毛髪の長さを増大させることが可能であり(実施例2参照)、したがって、脱毛の治療および予防におけるその有効性が確認される。
DETAILED DESCRIPTION OF THE INVENTIONThe inventors have unexpectedly observed that creatine can cause a significant increase in the level of DNA synthesis in those cells when applied to dermal papilla cells (Examples). 1). It has been suggested that dermal papilla cells are present in hair follicles and are involved in hair growth by modulating the proliferation and differentiation activities of keratinocytes (matrix cells) (Shimaoka et al., J. Dermatol. Sci .7 (Suppl): S79-S83, 1994). Therefore, an attempt was made to investigate whether an increase in DNA synthesis could result in an actual increase in hair growth. Again, unexpectedly, applying creatine in as little as 1 mM increases the actual hair length in the plugs at a statistically significant level relative to untreated controls. (See Example 2), thus confirming its effectiveness in the treatment and prevention of hair loss.
クレアチンは、通常は心臓、骨格筋、脳、および網膜のような種々の哺乳動物組織中に存在する天然の物質である。これまでに、たとえば、グルコース代謝障害の治療(米国特許第6,075,031号);肥満症の治療(米国特許第5,998,457号);および皮膚損傷の治療(米国特許第6,242,491号)において、多くの治療的用法が見いだされてきた。出願人の知るかぎり、毛髪成長の促進に使用することはこれまで知られていなかった。本発明に利用されるクレアチンは、天然に由来しうるか(すなわち、生体物質から直接単離しうるか)または合成的もしくは半合成的に取得しうる。クレアチンそれ自体を用いる以外に、クレアチンの誘導体または類似体を用いて、本方法を利用することもできる。そのような物質の例としては、クレアチンリン酸およびシクロクレアチンが挙げられるが、これらに限定されるものではなく;他のクレアチン類似体も知られており、たとえば、米国特許第6,075,031号(その内容は参照により本明細書に組み入れられるものとする)に開示されている。本発明に関連して使用する場合、「クレアチン化合物(複数可)」という用語は、クレアチンおよび同一タイプの刺激活性を呈するクレアチン類似体の両方を意味する。本方法で利用される毛嚢刺激有効量とは、毛嚢の毛髪成長を未処置の毛嚢で観測される成長よりも少なくとも20%増進させることのできる量、好ましくは少なくとも40%、より好ましくは少なくとも50%、最も好ましくは少なくとも80%増進させることのできる量である。 Creatine is a natural substance that normally exists in various mammalian tissues such as the heart, skeletal muscle, brain, and retina. To date, a number of therapeutic uses, for example, in the treatment of impaired glucose metabolism (US Pat. No. 6,075,031); the treatment of obesity (US Pat. No. 5,998,457); and the treatment of skin damage (US Pat. No. 6,242,491). Has been found. As far as the applicant is aware, it has not been known to be used to promote hair growth. The creatine utilized in the present invention can be derived from nature (ie, can be isolated directly from biological material) or can be obtained synthetically or semi-synthetically. In addition to using creatine itself, the method can also be used with creatine derivatives or analogs. Examples of such materials include, but are not limited to, creatine phosphate and cyclocreatine; other creatine analogs are also known, eg, US Pat. No. 6,075,031 (contents thereof). Are incorporated herein by reference). As used in the context of the present invention, the term “creatine compound (s)” means both creatine and creatine analogs that exhibit the same type of stimulatory activity. A hair follicle stimulating effective amount utilized in the present method is an amount that can increase hair follicle hair growth by at least 20% over growth observed in untreated hair follicles, preferably at least 40%, more preferably Is an amount that can be increased by at least 50%, most preferably at least 80%.
クレアチン化合物は、毛髪および頭皮に適用するために局所製剤の形態で使用される。製剤の組成は、決定的に重要であるわけではなく、媒体は、局所適用が許容できるものであればなんでもよいが、特定的には、組成は、毛髪または頭皮への適用に適合する。製剤は、シャンプー、ヘアリンス、コンディショナー、ポマード、ジェル、または毛髪のトリートメントに通常使用される任意の他の処方物として適用しうる。好ましい実施形態では、組成物は、シャンプー、コンディショナー、またはリンスとして適用される。実用上、製剤に使用される「有効量」は、全組成物の重量を基準にして、一般的には約0.0001〜約20%、好ましくは約0.001〜約10%、より好ましくは約0.01〜約10%であろう。 Creatine compounds are used in the form of topical formulations for application to the hair and scalp. The composition of the formulation is not critical, and the medium can be anything that is acceptable for topical application, but in particular the composition is adapted for application to the hair or scalp. The formulation may be applied as a shampoo, hair rinse, conditioner, pomade, gel, or any other formulation normally used for hair treatment. In preferred embodiments, the composition is applied as a shampoo, conditioner, or rinse. In practice, the “effective amount” used in the formulation is generally about 0.0001 to about 20%, preferably about 0.001 to about 10%, more preferably about 0.01 to about 20%, based on the weight of the total composition. It will be about 10%.
前記組成物は、1種以上のクレアチン化合物だけを活性薬剤として含有するものであってもよいし、毛髪および頭皮に対して同様に有益な作用を呈する他の活性薬剤と併用されたものであってもよい。毛髪成長にとくに有益な効果は、少なくとも1種の追加のエネルギー増強活性成分、たとえば、アデノシン、ATP、ADP、AMP、オキサロ酢酸(オキサロアセテート)、NADH、NADPH、またはカルニチンもしくはその誘導体(アセチルカルニチンやパルミトイルカルニチンなど)との併用により達成しうる。これらの各活性成分は、毛髪の成長に対して同様に有益な作用を有しうる。クレアチンを含めて組成物に使用されるエネルギー誘導化合物の全量は、約0.0001〜約10重量%、好ましくは約0.01〜約5%であろう。とくに好ましいのは、クレアチンと、5'-AMP、NADH、およびカルニチンのうちの少なくとも1種と、の併用であり、きわめて有効な併用は、組成物中で4種の成分すべてを用いたときに得られる。 The composition may contain only one or more creatine compounds as an active agent, or may be used in combination with other active agents that similarly exhibit beneficial effects on the hair and scalp. May be. Particularly beneficial effects on hair growth are at least one additional energy enhancing active ingredient such as adenosine, ATP, ADP, AMP, oxaloacetate (oxaloacetate), NADH, NADPH, or carnitine or its derivatives (acetylcarnitine and This can be achieved in combination with palmitoylcarnitine and the like. Each of these active ingredients may have a beneficial effect on hair growth as well. The total amount of energy-inducing compound used in the composition, including creatine, will be from about 0.0001 to about 10% by weight, preferably from about 0.01 to about 5%. Particularly preferred is a combination of creatine and at least one of 5′-AMP, NADH, and carnitine, and a highly effective combination is when all four components are used in the composition. can get.
本発明に係る毛髪成長組成物はまた、場合により、毛髪成長に対して有益な作用を有する他の活性成分を含んでいてもよい。1つのタイプの追加の活性成分は、5-アルファレダクターゼ阻害剤である。そのような化合物は、毛髪成長の促進を支援することが知られており、例としては、ソーパルメット(Serenoa)抽出物、Emblica officianalis抽出物、ベータ-グリシルレチン酸、エストラジオール、エストロン、プロゲステロン、またはアザステロイド類(たとえば、フィナステリドもしくはズタステリド)が挙げられるが、これらに限定されるものではない。レダクターゼ阻害剤は天然由来であることがとくに好ましい。とりわけ好ましい天然由来の阻害剤は、Actives International, Ramsey, New JerseyからViapure Sabalとして市販されている精製ソーパルメットベリー抽出物である。レダクターゼ阻害剤の使用量は、物質のアイデンティティーおよび効力に依存してさまざまであろうが、物質に対する公知の有効範囲に一致するであろう。量は、一般的には約.0001〜10%の範囲内であろうが、好ましい物質であるソーパルメット抽出物の場合、この量は、好ましくは約.001〜約2%であろう。 The hair growth composition according to the invention may also optionally contain other active ingredients that have a beneficial effect on hair growth. One type of additional active ingredient is a 5-alpha reductase inhibitor. Such compounds are known to assist in promoting hair growth, such as, for example, Serenoa extract, Emblica officianalis extract, beta-glycyrrhetinic acid, estradiol, estrone, progesterone, or azasteroids Class (for example, finasteride or zosteride), but is not limited thereto. It is particularly preferred that the reductase inhibitor is naturally derived. A particularly preferred naturally-occurring inhibitor is a purified soap palmetto berry extract commercially available as Viapure Sabal from Actives International, Ramsey, New Jersey. The amount of reductase inhibitor used will vary depending on the identity and potency of the substance, but will be consistent with the known effective range for the substance. The amount will generally be in the range of about .0001 to 10%, but in the case of the preferred material soap palmetto extract, this amount will preferably be about .001 to about 2%.
本発明に係る組成物はまた、1種以上の抗炎症剤を組み込むことにより改良することもできる。有用な抗炎症物質の例としては、ルテオリン、アメントフラボン、茯苓キノコ抽出物(Poria cocos)、グリチルレチン酸ステアリルおよび他の抗炎症グリチルリチン酸誘導体、マヌカ油、エミュー油、エキナセア、カモミール(マトリカリア油)、黄岑(scuttelaria)抽出物、ヨモギ抽出物、ゲンチアナ抽出物、ダイズタンパク質、キンセンカ、カイエン、ウコン、セイヨウシロヤナギ、シアリル糖質(たとえば、3'シアリルラクトース)などが挙げられるが、これらに限定されるものではない。製剤中の抗炎症剤の全量は、通常は約.0001〜約10%の範囲内であろう。 The composition according to the invention can also be improved by incorporating one or more anti-inflammatory agents. Examples of useful anti-inflammatory substances include luteolin, amentoflavone, salmon mushroom extract (Poria cocos), stearyl glycyrrhetinate and other anti-inflammatory glycyrrhizic acid derivatives, manuka oil, emu oil, echinacea, chamomile (matricaria oil) , Scuttelaria extract, mugwort extract, gentian extract, soy protein, calendula, cayenne, turmeric, white willow, sialyl carbohydrate (e.g., 3 'sialyl lactose), etc. It is not something. The total amount of anti-inflammatory agent in the formulation will usually be in the range of about .0001 to about 10%.
毛髪成長に直接寄与するものではないが、うぶ毛のようなより明色のあまり目立たない毛髪を暗色化することにより製品の全体的有益性を向上させる色素沈着増強剤を製剤中に組み込むことが望ましいこともある。有用な色素沈着増強剤の例は、N-アセチル-L-チロシン、チロシン、フォルスコリン、フェニルアラニン、L-DOPA、メチルキサンチン、またはα-メラニン細胞刺激ホルモンである。色素沈着増強剤は、約0.0001〜約10%の量で使用されるであろう。 Incorporating a pigmentation enhancer into the formulation that does not contribute directly to hair growth but improves the overall benefit of the product by darkening less bright, less prominent hair such as vellus hair Sometimes desirable. Examples of useful pigmentation enhancers are N-acetyl-L-tyrosine, tyrosine, forskolin, phenylalanine, L-DOPA, methylxanthine, or α-melanocyte stimulating hormone. The pigmentation enhancer will be used in an amount of about 0.0001 to about 10%.
血管拡張増強剤もまた、製剤の任意成分である。血管拡張は、長い間、頭皮だけでなく毛髪が成長する皮膚の他のすべての領域における毛髪成長の増進に関連付けられてきた。したがって、1種以上の血管拡張剤を使用することにより、エネルギー増大化合物の活性を補完し、製剤の全体的有効性を向上させることができる。有用な血管拡張剤の例としては、アルギニン、チョウセンニンジン抽出物、イチョウ抽出物、センブリ抽出物、塩化カルプロニウム(calpronium chloride)、塩酸ジフェンヒドラミン、ガンマ-オリザノール、プロスタグランジン類、ビタミンE誘導体(たとえばビタミンEニコチネート)、ピナシジル、ミノキシジル、フタリド類、キナ抽出物、トウガラシ抽出物、橙皮抽出物、およびシトロン抽出物が挙げられるが、これらに限定されるものではない。この成分は、存在する場合、通常、約0.0001〜約10%の量で使用されるであろう。 A vasodilator enhancer is also an optional component of the formulation. Vasodilation has long been associated with enhanced hair growth not only in the scalp but in all other areas of the skin where hair grows. Thus, the use of one or more vasodilators can complement the activity of the energy enhancing compound and improve the overall effectiveness of the formulation. Examples of useful vasodilators include arginine, ginseng extract, ginkgo biloba extract, assembly extract, calpronium chloride, diphenhydramine hydrochloride, gamma-oryzanol, prostaglandins, vitamin E derivatives (e.g. vitamins E nicotinate), pinacidil, minoxidil, phthalides, quina extract, red pepper extract, orange peel extract, and citron extract, but are not limited thereto. This component, if present, will normally be used in an amount of about 0.0001 to about 10%.
前記組成物はまた、脱毛の一因となる可能性のあるフリーラジカルを抑制したり太陽の乾燥作用や他の光損傷から毛髪を保護したりする1種以上の抗酸化剤の存在により、有益な効果が付与されうる。有用な抗酸化剤の例としては、イチョウ葉、ベータカロテン、緑茶、アスコルビン酸およびその誘導体(たとえば、ナトリウムアスコルビルホスフェートやマグネシウムアスコルビルホスフェートなど)、カルノシン酸(ローズマリー)、レスベラトロールおよびその誘導体、N-アセチルシステイン、ならびにBHTおよびBHAが挙げられるが、これらに限定されるものではない。緑茶は、他の抗酸化剤の場合と同様に、抽出物の活性成分(たとえば、緑茶から得られるEGCG(エピガロカテキン(epigallcatechin)ガレート)のようなカテキン系フラボノイド類、ローズマリー抽出物から得られる活性成分など)の形態だけでなく、抽出物の形態または抗酸化剤の任意の他の公知の形態で存在しうる。抗酸化剤は、使用する場合、約0.0001〜約10%の量で存在するであろう。 The composition is also beneficial due to the presence of one or more antioxidants that suppress free radicals that may contribute to hair loss and protect the hair from sun drying and other light damage. Effects can be imparted. Examples of useful antioxidants include ginkgo biloba, beta-carotene, green tea, ascorbic acid and its derivatives (e.g. sodium ascorbyl phosphate and magnesium ascorbyl phosphate), carnosic acid (rosemary), resveratrol and its derivatives, Examples include, but are not limited to, N-acetylcysteine, and BHT and BHA. Green tea, like other antioxidants, is obtained from catechin-based flavonoids such as EGCG (epigallcatechin gallate obtained from green tea), rosemary extract, as in the case of other antioxidants. In the form of an extract or any other known form of antioxidant. When used, the antioxidant will be present in an amount of about 0.0001 to about 10%.
前記組成物は、1種以上の細胞分化活性化剤をさらに含みうる。とりわけ好ましいのは、クラリーセージなどのセージの抽出物および/またはそれから取得可能なスクラレオリドのような任意の分化活性化合物である。有用な分化活性化合物の他の例は、フォルスコリン、7-デヒドロコレステロール、およびビタミンD3類似体である。この目的にとりわけ好ましい成分は、Avoca/RJ Reynoldsから市販されているクラリーセージ発酵抽出物である。使用量は、存在する場合、約0.001〜約10%、好ましくは約.01〜約1%であろう。 The composition may further comprise one or more cell differentiation activators. Especially preferred are any differentiation active compounds such as sage extracts such as clary sage and / or sclareolide obtainable therefrom. Other examples of useful differentiation active compounds are forskolin, 7-dehydrocholesterol, and vitamin D3 analogs. A particularly preferred ingredient for this purpose is a clari sage fermentation extract commercially available from Avoca / RJ Reynolds. The amount used, if present, will be from about 0.001 to about 10%, preferably from about 0.01 to about 1%.
毛髪成長製剤はまた、毛髪構造を形成および支持する基底膜および真皮において支持を促進するファーミング成分をも含みうる。ファーミング成分の例は、皮膚中のコラーゲンおよび/またはエラスチンの量を増大させる化合物、たとえば、コラゲナーゼおよびもしくはエラスターゼ阻害剤またはコラーゲンもしくはエラスチン合成増強剤である。そのような化合物としては、トリテルペノイド含有抽出物および精製化合物、たとえば、シラカバ樹皮抽出物、シダレカンバ樹皮抽出物、Boswellia抽出物、ベアベリー抽出物、Centella asiatica抽出物、Mimosa tenuiflora樹皮抽出物、またはPygeum (Prunus) africanum抽出物、ならびにこれらの抽出物中に存在しうる個別活性化合物、たとえば、ベツリノール(ベツリン)、ベツリン酸、ボスウェル酸、ウルソール酸、オレアノール酸、オレアノール、アシアチコシド、アシアト酸、およびマダガシン酸(madagassic acid);フェノール類含有抽出物、たとえば、緑茶抽出物およびリンゴ抽出物、ならびにその中に含まれる化合物、たとえば、EGCG、ECG、カテキン類、フェニルプロパノイド類およびフロレチン;さらにはコラーゲン合成を増大させるためのビタミンCおよびその誘導体が挙げられるが、これらに限定されるものではない。好ましいコラゲナーゼ阻害剤は、テペズコヒテとして知られるMimosa tenuiflora抽出物であり、好ましいビタミンC誘導体は、BV-OSVである。ファーミング剤は、組成物の約.001〜約10重量%の量で使用される。 The hair growth formulation may also include a farming component that promotes support in the basement membrane and dermis that forms and supports the hair structure. Examples of farming ingredients are compounds that increase the amount of collagen and / or elastin in the skin, such as collagenase and / or elastase inhibitors or collagen or elastin synthesis enhancers. Such compounds include triterpenoid-containing extracts and purified compounds such as birch bark extract, weeping birch bark extract, Boswellia extract, bearberry extract, Centella asiatica extract, Mimosa tenuiflora bark extract, or Pygeum (Prunus ) africanum extracts, and the individual active compounds that may be present in these extracts, such as betulinol (betulin), betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, and madagassic acid); phenols-containing extracts, such as green tea and apple extracts, and compounds contained therein, such as EGCG, ECG, catechins, phenylpropanoids and phloretins; and further increase collagen synthesis For vitamin C and They include derivatives of, but not limited thereto. A preferred collagenase inhibitor is Mimosa tenuiflora extract known as Tepezcochite, and a preferred vitamin C derivative is BV-OSV. Firming agents are used in amounts of about .001 to about 10% by weight of the composition.
前記組成物はまた、毛髪または頭皮の状態を改善するのに有用である他の非活性物質、たとえば、保湿剤、ヘアコンディショナーおよびデタングラー、増粘剤、ゲル化剤、皮膜形成剤、芳香剤などを含有しうる。活性成分が添加されて適用される媒体は、毛髪に適用するために典型的に使用される任意の形態、たとえば、クリーム、ジェル、スプレー、ムースなどの形態をとりうる。しかしながら、一般的には、製剤は完全には水性でないことが好ましい。 The composition may also be other inactive substances that are useful for improving the condition of the hair or scalp, such as humectants, hair conditioners and detanglers, thickeners, gelling agents, film formers, fragrances, etc. May be contained. The medium to which the active ingredient is added can be in any form typically used for application to the hair, such as creams, gels, sprays, mousses, and the like. In general, however, it is preferred that the formulation is not completely aqueous.
クレアチン化合物含有組成物は、さまざまな用途で使用することができる。たとえば、一実施形態では、本発明は、毛髪の生えかわりの通常の周期を保持し、加齢に伴って生じる通常の菲薄化を減少または予防すべく、健康な毛髪および頭皮にクレアチン化合物を適用することを包含する。本発明に係る組成物はまた、頭皮上にすでに存在する毛髪を保持したり、すでに存在する毛髪の直径を増大させたりするうえにも役立つであろう。他の実施形態では、脱毛の初期段階にある人または禿頭症の遺伝的危険性はあるがまだ禿げていない人の毛髪および頭皮に組成物を適用することにより、脱毛を予防または遅延して、健康な毛嚢における毛髪成長を保持したり、すでに実質的に不活性になっている可能性のある毛嚢の成長を回復させたりする。過度に引き抜かれたかまたは薄くなった眉毛(本明細書中では、「毛髪」という用語に包含されると解釈されるものとする)の回復もまた、可能である。最後に、脱毛症を患っている人に本方法を適用することにより、脱毛を逆転させたり、既存の毛嚢において通常の毛髪成長を再開させたりする。すでに述べたように、この方法は、男性および女性の両方に効果的に適用することが可能であり、しかも脱毛の究極的原因に関係なく、すなわち、男性型禿頭症、加齢に伴って自然に生じる菲薄化、または化学療法もしくは他の薬剤暴露に起因する脱毛のいずれであるかにかかわらず、使用可能である。成果を得るうえで必須というわけではないが、最適な毛髪成長は、一週間に少なくとも3〜5回の適用頻度のときに得られるであろう。また、治療期間中、クレアチン含有組成物を毎日使用することがとくに推奨される。その使用の時期は、脱毛の原因に基づいて決定されるであろう。たとえば、薬剤暴露に起因する一時的な脱毛では、有害な刺激が除去された後、続いて毛髪が満足すべきレベルに再成長するまで、一時的に定期的使用が必要になるにすぎないであろう。しかしながら、原因因子が常に存在するパターン性または加齢性の禿頭症または毛髪菲薄化では、長期間の適用が好ましい。すなわち、使用者の生涯にわたり、定期的に適用が行われることになろう。この場合、本明細書中では、局所適用の期間は、使用者の生涯にわたりうるが、好ましくは少なくとも約1ヶ月間、より好ましくは約3ヶ月間〜約20年間、より好ましくは約6ヶ月間〜約10年間、さらにより好ましくは約1年間〜約5年間、または使用者が自分の毛髪成長を保持することに関心を有するかぎり長い期間、を意味する。製剤の適用量は、製剤の形態によって異なるであろうが、通常は、同一タイプの製剤に使用される業界公認の方法に準拠するであろう。代表的な適用方法は、治療を必要とする領域に製剤を1日1回または2回適用してから数時間にわたり製剤を所定の位置に静置することを含むであろう。以下の実施例により本発明についてさらに具体的に説明するが、これに限定されるものではない。 The creatine compound-containing composition can be used in various applications. For example, in one embodiment, the present invention applies a creatine compound to healthy hair and scalp to maintain a normal cycle of hair replacement and to reduce or prevent normal thinning that occurs with aging. To include. The composition according to the invention may also be useful for retaining hair already present on the scalp or increasing the diameter of hair already present. In other embodiments, hair loss is prevented or delayed by applying the composition to the hair and scalp of a person at an early stage of hair loss or a person at genetic risk of baldness but not yet bald, Maintains hair growth in healthy hair follicles or restores hair follicle growth that may already be substantially inactive. Recovery of overdrawn or thinned eyebrows (which shall be construed herein as encompassed by the term “hair”) is also possible. Finally, applying this method to a person suffering from alopecia reverses hair loss or resumes normal hair growth in existing hair follicles. As already mentioned, this method can be effectively applied to both men and women, and regardless of the ultimate cause of hair loss, i.e., male pattern baldness, natural with aging It can be used regardless of whether it is thinning or hair loss resulting from chemotherapy or other drug exposure. Although not essential for achieving results, optimal hair growth will be obtained at a frequency of application of at least 3-5 times per week. It is also particularly recommended that the creatine-containing composition be used daily during the treatment period. The timing of its use will be determined based on the cause of hair loss. For example, temporary hair loss due to drug exposure only requires periodic use once the harmful irritation is removed and then the hair re-grows to a satisfactory level. I will. However, for pattern or age-related baldness or hair thinning where the causal factor is always present, long-term application is preferred. That is, it will be applied periodically over the life of the user. In this case, as used herein, the period of topical application may extend over the lifetime of the user, but preferably is at least about 1 month, more preferably from about 3 months to about 20 years, more preferably about 6 months. Means about 10 years, even more preferably about 1 year to about 5 years, or as long as the user is interested in maintaining his hair growth. The dosage of the formulation will vary depending on the form of the formulation, but will usually conform to industry-recognized methods used for the same type of formulation. A typical method of application would involve applying the formulation once or twice daily to the area in need of treatment and allowing the formulation to stand in place for several hours. The present invention will be described more specifically with reference to the following examples, but is not limited thereto.
実施例1. この実施例では、クレアチンに暴露されたときの真皮乳頭の増殖の増進について具体的に説明する。
方法: Cell Applications Incorporated (San Diego, CA)から正常ヒト真皮乳頭細胞を入手した。これは、毛栓に由来する真皮乳頭細胞を単離したものである。乳頭細胞を24ウェルプレート中で70%まで増殖させた。0.25〜1mMクレアチン(Sigma)の範囲内のクレアチン(Sigma)および0.25〜0.5mMオキサロアセテート(Sigma)の投与量で、これらの細胞を処置した。[H]3-チミジン標識(1μCi/ml)を各ウェルに添加する前の24時間にわたり、これらの処置を行った。24時間後、細胞増殖の指標であるDNA合成を[H]3-チミジン取込みの関数として測定した。
Example 1 This example demonstrates the enhancement of dermal papilla proliferation when exposed to creatine.
Methods: Normal human dermal papilla cells were obtained from Cell Applications Incorporated (San Diego, CA). This is an isolated dermal papilla cell derived from a hair plug. Papilla cells were grown to 70% in 24-well plates. These cells were treated with doses of creatine (Sigma) and 0.25-0.5 mM oxaloacetate (Sigma) within the range of 0.25-1 mM creatine (Sigma). These treatments were performed for 24 hours prior to the addition of [H] 3 -thymidine label (1 μCi / ml) to each well. After 24 hours, DNA synthesis, an indicator of cell proliferation, was measured as a function of [H] 3 -thymidine incorporation.
結果: クレアチンは乳頭細胞においてDNA合成を有意に増加させることが判明した(表1および2参照)。0.25mMでは、クレアチンは、DNA合成の36%増加を引き起こした。0.5mMでは、クレアチンは、DNA合成の25%増加を引き起こした。1mMでは、クレアチンは、DNA合成の6%増加を引き起こした。オキサロアセテートもまた、乳頭細胞においてDNA合成を用量依存的に有意に増加させることが判明した。0.25mMでは、オキサロアセテートは、DNA合成の22%増加を引き起こした。0.5mMでは、オキサロアセテートは、DNA合成の33%増加を引き起こした。1mMでは、オキサロアセテートは、DNA合成の38%増加を引き起こした。等価濃度のAMP(.25mMで1493%増加、0.5mMで1930%増加、1mMで1449%増加)およびATP(.25mMで1411%増加、.5mMで1201%増加)を用いたときにも、肯定的な結果が観測された。 Results: Creatine was found to significantly increase DNA synthesis in papillary cells (see Tables 1 and 2). At 0.25 mM, creatine caused a 36% increase in DNA synthesis. At 0.5 mM, creatine caused a 25% increase in DNA synthesis. At 1 mM, creatine caused a 6% increase in DNA synthesis. Oxaloacetate was also found to significantly increase DNA synthesis in papillary cells in a dose-dependent manner. At 0.25 mM, oxaloacetate caused a 22% increase in DNA synthesis. At 0.5 mM, oxaloacetate caused a 33% increase in DNA synthesis. At 1 mM, oxaloacetate caused a 38% increase in DNA synthesis. Affirmative when using equivalent concentrations of AMP (1493% increase at .25mM, 1930% increase at 0.5mM, 1449% increase at 1mM) and ATP (1411% increase at .25mM, 1201% increase at .5mM) Results were observed.
考察: エネルギー増強基質であるクレアチン、AMP、オキサロアセテート、およびATPは、それぞれ、真皮乳頭細胞においてDNA合成を増加させることが判明した。この増加は、統計的に有意であった。
実施例2. この実施例では、クレアチンに暴露された毛栓において観測された毛髪成長の増進について具体的に説明する。
方法: East Wood Medical Hair Transplant Surgery (Garden City, NY)から毛栓を入手した。これらの毛栓を、文献に記載されている毛栓培地(DMEM, 10% FBS, 1% PS, 25mgインスリン, 25μgフンギゾン)中で平衡化させた。これらの毛栓を到着初日に顕微鏡下で観察し、1mMのクレアチンで処置した(対照群およびクレアチン群に対して、それぞれn=6)。次に、これらの毛栓を37℃、5% CO2でインキュベーター内に保持した。3、7、および10日目に、再処置を行い、測定も行った。
Example 2. This example illustrates the enhancement of hair growth observed in hair plugs exposed to creatine.
Methods: Hair plugs were obtained from East Wood Medical Hair Transplant Surgery (Garden City, NY). These plugs were equilibrated in the plug medium described in the literature (DMEM, 10% FBS, 1% PS, 25 mg insulin, 25 μg fungizone). These capillaries were observed under the microscope on the first day of arrival and treated with 1 mM creatine (n = 6 for control and creatine groups, respectively). Next, these caps were kept in an incubator at 37 ° C. and 5% CO 2 . On days 3, 7, and 10, retreatment was performed and measurements were taken.
結果: 毛栓は一定の速度で成長することが判明した。未処置の群では、0日目と比較して3日目では0.48mmの平均成長であった。7日目では0.73mmの平均成長および10日目では0.82mmの平均成長であった。クレアチンは未処置の毛栓と比較してこれらの毛栓の成長速度を有意に増加させることが判明した。3日目では0.95mm、7日目では1.32mm、および10日目では1.43mmの平均成長であった(表3、4、および5参照)。これらの増加はすべて、統計的に有意であった。 Results: The plugs were found to grow at a constant rate. The untreated group had an average growth of 0.48 mm on day 3 compared to day 0. On day 7, the average growth was 0.73 mm and on day 10, the average growth was 0.82 mm. Creatine was found to significantly increase the growth rate of these plugs compared to untreated plugs. The average growth was 0.95 mm on day 3, 1.32 mm on day 7, and 1.43 mm on day 10 (see Tables 3, 4 and 5). All these increases were statistically significant.
考察: クレアチンは毛栓における毛髪成長を有意に増進させることが判明した。この増進は、未処置の毛栓と比較してほぼ2倍であった。我々は、先に、クレアチンが真皮乳頭細胞においてDNA合成を増加させることを観測した。真皮乳頭細胞は毛髪の成長に作用しモジュレートするので、我々は、クレアチンが真皮乳頭細胞の活性を増大させることにより毛栓成長を増進させているのではないかと仮定する。
実施例3: この実施例では、エネルギー増強化合物のブレンドの毛髪成長促進活性について具体的に説明する。
方法: East Wood Medical Hair Transplant Surgery (Garden City, NY)から毛栓を入手した。これらの毛栓を、文献に記載されている毛栓培地(DMEM, 10% BCS, 1% PS, 25μgフンギゾン)中で平衡化させた。初日(0日目)に毛栓の測定を行った。0、0.01、0.1、および1×のエネルギーブレンドで毛栓を処置した。1×のエネルギーブレンドは、0.25mMのAMP、2.5mMのクレアチン、2mMのL-カルニチン、および2mMのNADHに対応する。4日後、再び測定を行った後、それらのそれぞれの濃度を有する新たな培地で再処置を行った(対照群および処置群に対して、それぞれ、n=12)。これらの毛栓を37℃、5% CO2でインキュベーター内に保持した。3日後、再び、測定および再処置を行った。0日目に対して、4日目、7日目、12日目、および14日目の長さを比較することにより、毛栓成長を測定した。14日目、異なる処置群からの代表的な毛栓をBRDUで標識化した。次に、これらの毛栓をParagon Biotechnologyに送って組織切片を調べた。活性増殖細胞のBRDU標識化を評価した。
Example 3: This example illustrates the hair growth promoting activity of a blend of energy enhancing compounds.
Methods: Hair plugs were obtained from East Wood Medical Hair Transplant Surgery (Garden City, NY). These plugs were equilibrated in the plug medium described in the literature (DMEM, 10% BCS, 1% PS, 25 μg fungizone). The capillaries were measured on the first day (Day 0). The plugs were treated with 0, 0.01, 0.1, and 1 × energy blends. The 1 × energy blend corresponds to 0.25 mM AMP, 2.5 mM creatine, 2 mM L-carnitine, and 2 mM NADH. After 4 days, measurements were taken again and then re-treated with fresh media having their respective concentrations (n = 12 for control and treatment groups, respectively). These plugs were kept in an incubator at 37 ° C. and 5% CO 2 . Three days later, measurement and retreatment were performed again. Capillary growth was measured by comparing lengths on days 4, 7, 12, and 14 versus day 0. On day 14, representative hair plugs from different treatment groups were labeled with BRDU. These plugs were then sent to Paragon Biotechnology to examine tissue sections. The BRDU labeling of active proliferating cells was evaluated.
結果: 毛栓は一定の速度で成長することが判明した。未処置の毛栓では、0日目と比較して、4、6、10、および14日目における毛髪の長さの平均増加は、0.11、0.16、0.2、0.26mmであった 1)。0.01×のエネルギーブレンドで処置された毛栓では、0日目と比較して、4、6、10、および14日目における毛髪の長さの平均増加は、0.24、0.33、0.41、0.47mmであった。0.1×のエネルギーブレンドで処置された毛栓では、0日目と比較して、4、6、10、および14日目における毛髪の長さの平均増加は、0.41、0.54、0.54、0.64mmであった。1×のエネルギーブレンドで処置された毛栓では、0日目と比較して、4、6、10、および14日目における毛髪の長さの平均増加は、0.21、0.28、0.35、0.49mmであった。毛栓成長は、エネルギーブレンドの0.1×処置で268%、エネルギーブレンドの0.01×処置で116%、およびエネルギーブレンドの1×処置で87%程度増進された。さらに、毛球の免疫組織学的検査から、未処置の対照よりもエネルギーブレンドで処置された毛栓のほうが、より活発に増殖する細胞が存在することが判明した。 Results: The plugs were found to grow at a constant rate. For untreated hair plugs, the average increase in hair length on days 4, 6, 10, and 14 compared to day 0 was 0.11, 0.16, 0.2, 0.26 mm 1). For capillas treated with the 0.01 × energy blend, the average increase in hair length on days 4, 6, 10, and 14 compared to day 0 was 0.24, 0.33, 0.41, and 0.47 mm. there were. For capillas treated with a 0.1 × energy blend, the average increase in hair length on days 4, 6, 10, and 14 compared to day 0 was 0.41, 0.54, 0.54, and 0.64 mm. there were. For capillas treated with a 1 × energy blend, the average increase in hair length on days 4, 6, 10, and 14 compared to day 0 was 0.21, 0.28, 0.35, and 0.49 mm. there were. Capillar growth was improved by as much as 268% with the energy blend 0.1 × treatment, 116% with the energy blend 0.01 × treatment, and 87% with the energy blend 1 × treatment. Furthermore, immunohistologic examination of the hair bulbs revealed that there were more actively proliferating cells in the hair plugs treated with the energy blend than in the untreated controls.
考察: AMP、クレアチン、L-カルニチン、およびNADHを含有するエネルギーブレンド処置剤は、毛栓成長を増進させることが判明した。この処置ブレンドは、0.025mMのAMP、0.25mMのクレアチン、0.2mMのL-カルニチン、および0.2mMのNADHを用いたとき、最適であることが判明した。4日後、未処置の対照と比較して、268%までの毛栓成長が観測された。さらに、BRDU標識化からも、エネルギーブレンドで処置された毛栓の毛球においてより活発に増殖する細胞が明らかにされた。先述の濃度よりも高い10×の濃度の処置ブレンドでは、毛髪成長の増進は、それほど効果的ではなかった(87%)。これは、過飽和またはカルニチンおよびNADHによるpH低下が原因であろう。毛髪成長の観測された増進は部分的には真皮乳頭細胞活性および増殖因子放出の増大によるものと仮定される。先に、我々は、エネルギー技術を用いて処置された真皮乳頭細胞においてDNA合成の増加を観測した。
実施例4: この実施例では、本発明に係る組成物について具体的に説明する。量はすべて、全組成物に対する重量パーセントである。
Example 4: This example illustrates the composition according to the present invention. All amounts are weight percent relative to the total composition.
Claims (23)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45119303P | 2003-02-28 | 2003-02-28 | |
US60/451,193 | 2003-02-28 | ||
US49591503P | 2003-08-18 | 2003-08-18 | |
US60/495,915 | 2003-08-18 | ||
PCT/US2004/005765 WO2004078117A2 (en) | 2003-02-28 | 2004-02-25 | Method for increasing hair growth |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006519181A JP2006519181A (en) | 2006-08-24 |
JP4709739B2 true JP4709739B2 (en) | 2011-06-22 |
Family
ID=32965535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006501201A Expired - Lifetime JP4709739B2 (en) | 2003-02-28 | 2004-02-25 | How to improve hair growth |
Country Status (7)
Country | Link |
---|---|
US (3) | US7790768B2 (en) |
EP (2) | EP1599169A4 (en) |
JP (1) | JP4709739B2 (en) |
AU (1) | AU2004218468B2 (en) |
CA (2) | CA2516621C (en) |
ES (1) | ES2641280T3 (en) |
WO (1) | WO2004078117A2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL132625A (en) * | 1999-10-28 | 2007-06-17 | Avi Dascalu | Composition for inducing hair growth |
EP1599169A4 (en) * | 2003-02-28 | 2008-01-23 | E L Management Corp | Method for increasing hair growth |
US7452527B2 (en) * | 2003-03-28 | 2008-11-18 | Murad, Inc. | Methods of promoting hair growth |
WO2005044205A1 (en) * | 2003-11-11 | 2005-05-19 | Shiseido Company, Ltd. | Method and composition for hair thickening |
WO2005123032A2 (en) * | 2004-06-15 | 2005-12-29 | The Boots Company Plc | Haircare compositions and methods |
DE102005011957A1 (en) * | 2005-03-14 | 2006-12-07 | Henkel Kgaa | New hair treatment composition containing L-carnitine or L-carnitine derivatives |
US8985124B2 (en) * | 2005-10-03 | 2015-03-24 | Pilaris Labs Llc | Method for treatment of hair loss with a combination of natural ingredients |
US8263053B2 (en) * | 2005-11-22 | 2012-09-11 | Access Business Group International | Hair treatment compositions |
US7914548B2 (en) * | 2006-04-17 | 2011-03-29 | Ustuner E Tuncay | Prevention or treatment of male pattern baldness method and device |
US20080059313A1 (en) * | 2006-08-30 | 2008-03-06 | Oblong John E | Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair |
DE102006042227A1 (en) * | 2006-09-06 | 2008-03-27 | Henkel Kgaa | Reduction of hair aging |
US20080175807A1 (en) * | 2007-01-24 | 2008-07-24 | Fujifilm Corporation | Composition for hair |
US8580236B2 (en) * | 2007-03-19 | 2013-11-12 | Richard P. De Maria | Hair sustaining formulation |
EP2014276A1 (en) * | 2007-06-20 | 2009-01-14 | Cognis IP Management GmbH | Cosmetic compositions comprising sclareolide and hesperidin methyl chalcone |
WO2009107075A1 (en) * | 2008-02-29 | 2009-09-03 | The Procter & Gamble Company | Hair care compositions and methods for increasing hair diameter and for immediate fuller/thicker hair appearance |
AU2009219789A1 (en) * | 2008-02-29 | 2009-09-03 | The Procter & Gamble Company | Hair care compositions and methods for increasing hair diameter |
CN101959496A (en) * | 2008-02-29 | 2011-01-26 | 宝洁公司 | Hair care composition and method of increasing hair diameter and additional benefits |
US20090274642A1 (en) * | 2008-04-30 | 2009-11-05 | Dawson Jr Thomas Larry | Hair Care Compositions for Preventing Oxidative Damage to Hair, Methods of Use, and Methods of Marketing Such Compositions |
JP2009298752A (en) * | 2008-06-17 | 2009-12-24 | Shiseido Co Ltd | Skin care preparation composition for external use |
DE102008040105A1 (en) * | 2008-07-03 | 2010-01-07 | Beiersdorf Ag | Stabilization of aqueous-alcoholic formulas by menthol |
FR2943253B1 (en) * | 2009-03-20 | 2011-04-22 | Oreal | COMPOSITION CONTAINING THE ASSOCIATION OF MADECASSOSIDE, ARGININE AND POLYSORBATE |
AU2011227198A1 (en) * | 2010-03-17 | 2012-10-04 | Arbonne International Llc | Topical skin care composition |
CA2816631C (en) * | 2010-12-21 | 2015-12-01 | The Procter & Gamble Company | Hair care compositions and methods to improve hair appearance |
US9138446B2 (en) * | 2011-06-08 | 2015-09-22 | Scott Alan Weisenfluh | EMU oil in combination with other active ingredients for treating skin imperfections |
US20140093466A1 (en) | 2012-10-02 | 2014-04-03 | The Procter & Gamble Company | Hair care compositions and methods of use |
JP2013103933A (en) * | 2011-11-16 | 2013-05-30 | Kn Commerce Co Ltd | Prophylactic and therapeutically improving agent for gray hair |
EP2838508A4 (en) | 2012-04-16 | 2015-03-11 | Zemtsov Entpr Llc | Formulations and methods for treatment of acne and inflammatory skin conditions |
CN103445971A (en) * | 2012-05-31 | 2013-12-18 | 祥茂生活科技股份有限公司 | Composition and method for promoting hair growth |
JP6179513B2 (en) * | 2012-07-05 | 2017-08-16 | ライオン株式会社 | Hair restorer composition |
ES2444273B1 (en) * | 2012-08-22 | 2014-12-09 | Lacer, S.A. | Topical pharmaceutical or cosmetic composition indicated to reduce or prevent hair loss and stimulate its growth |
JP2016514969A (en) * | 2013-03-19 | 2016-05-26 | ザ プロクター アンド ギャンブル カンパニー | Method for measuring metabolic index of hair follicle |
JP2014221749A (en) * | 2013-05-14 | 2014-11-27 | 昭和電工株式会社 | Hair growth-related factor activator |
WO2014186243A1 (en) | 2013-05-16 | 2014-11-20 | The Procter & Gamble Company | Hair thickening compositions and methods of use |
DE102013214713A1 (en) | 2013-07-29 | 2015-01-29 | Evonik Industries Ag | Formulations containing sphinganine |
CN104784068B (en) * | 2014-01-16 | 2018-01-12 | 拜尔斯道夫股份有限公司 | Hair loss preventing shampoo composition |
PT3160437T (en) * | 2014-06-26 | 2021-02-22 | Giuliani Spa | Composition suitable to preserve the physiological condition of skin and hair and reestablish their regenerative functions |
EP3974021B1 (en) | 2017-06-30 | 2023-06-14 | ONWARD Medical N.V. | A system for neuromodulation |
US10588906B2 (en) * | 2017-08-08 | 2020-03-17 | Seoul National University Hospital | Method of preventing hair loss or promoting hair growth by using phosphodiesterase 3 inhibitor |
WO2019110400A1 (en) | 2017-12-05 | 2019-06-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | A system for planning and/or providing neuromodulation |
EP3653256B1 (en) | 2018-11-13 | 2022-03-30 | ONWARD Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
KR102221365B1 (en) * | 2019-05-07 | 2021-03-02 | (주)케어젠 | Trolox Peptide Conjugate and Use Thereof |
DE19211698T1 (en) | 2019-11-27 | 2021-09-02 | Onward Medical B.V. | Neuromodulation system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002075A1 (en) * | 2000-07-06 | 2002-01-10 | Beiersdorf Ag | Use of creatine and/or creatine derivatives in cosmetic or dermatological preparations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1163908A (en) * | 1980-10-01 | 1984-03-20 | Shyun-Long Yun | Method for eliminating turbidity in a biological fluid and reagent therefor |
ES8503941A1 (en) * | 1982-10-27 | 1985-04-16 | Crinos Industria Farmaco | Cosmetic preparations for promoting trophism of the skin and of related hair follicles |
IT1258069B (en) * | 1992-04-10 | 1996-02-20 | COMPOSITION FOR TOPICAL USE WITH STIMULUS ACTIVITY FOR GROWTH, REGENERATION, PREVENTION OF ENRIGEMENT AND NATURAL REPIGMENTATION OF HAIR | |
US5741816A (en) | 1994-06-20 | 1998-04-21 | Tanabe Seiyaku Co., Ltd. | Hair-growth agent |
CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
WO1997002041A1 (en) * | 1995-07-03 | 1997-01-23 | Crandall Wilson T | Transdermal and oral treatment of androgenic alopecia |
AU721190B2 (en) | 1995-10-11 | 2000-06-29 | Avicena Group, Inc. | Use of creatine analogues for the treatment of disorders of glucose metabolism |
US5998457A (en) | 1995-10-26 | 1999-12-07 | Avicena Group, Inc. | Creatine analogues for treatment of obesity |
EP0998907B1 (en) * | 1998-10-26 | 2004-01-14 | Shiseido Company, Ltd. | Hair tonic composition comprising adenosine |
DE29906038U1 (en) | 1999-04-01 | 1999-07-15 | Maindok | Hair tonic |
US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
WO2002011717A1 (en) * | 2000-08-07 | 2002-02-14 | Juvenon, Inc. | Cosmetics to support skin metabolism |
DE10114561A1 (en) * | 2001-03-24 | 2002-09-26 | Wella Ag | Creatine, creatinine and/or their salts or derivatives are used in agents for repairing hair or increasing its gloss, volume or combability |
DE10119608A1 (en) * | 2001-04-21 | 2002-10-24 | Goldschmidt Ag Th | Hair treatment or post-treatment compositions for preventing or repairing damage caused by chemical treatment, e.g. perming or bleaching, containing creatine or its derivative as hair strengthening agent |
DE10136077A1 (en) | 2001-07-25 | 2003-02-13 | Beiersdorf Ag | Cosmetic or dermatological preparations containing creatinine and creatine, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis |
DE10136076A1 (en) * | 2001-07-25 | 2003-02-13 | Beiersdorf Ag | Cosmetic or dermatological preparations containing creatinine or its derivative, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis |
EP1599169A4 (en) * | 2003-02-28 | 2008-01-23 | E L Management Corp | Method for increasing hair growth |
-
2004
- 2004-02-25 EP EP04714661A patent/EP1599169A4/en not_active Withdrawn
- 2004-02-25 JP JP2006501201A patent/JP4709739B2/en not_active Expired - Lifetime
- 2004-02-25 CA CA002516621A patent/CA2516621C/en not_active Expired - Lifetime
- 2004-02-25 EP EP09168182.5A patent/EP2123252B1/en not_active Expired - Lifetime
- 2004-02-25 ES ES09168182.5T patent/ES2641280T3/en not_active Expired - Lifetime
- 2004-02-25 US US10/786,847 patent/US7790768B2/en active Active
- 2004-02-25 WO PCT/US2004/005765 patent/WO2004078117A2/en active IP Right Grant
- 2004-02-25 CA CA2678135A patent/CA2678135C/en not_active Expired - Lifetime
- 2004-02-25 AU AU2004218468A patent/AU2004218468B2/en not_active Expired
-
2009
- 2009-09-30 US US12/570,055 patent/US8232317B2/en not_active Expired - Lifetime
-
2010
- 2010-02-02 US US12/698,198 patent/US20100137238A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002075A1 (en) * | 2000-07-06 | 2002-01-10 | Beiersdorf Ag | Use of creatine and/or creatine derivatives in cosmetic or dermatological preparations |
Also Published As
Publication number | Publication date |
---|---|
US20100022651A1 (en) | 2010-01-28 |
EP2123252A1 (en) | 2009-11-25 |
CA2678135A1 (en) | 2004-09-16 |
US8232317B2 (en) | 2012-07-31 |
CA2516621A1 (en) | 2004-09-16 |
CA2516621C (en) | 2010-01-12 |
CA2678135C (en) | 2012-12-04 |
ES2641280T3 (en) | 2017-11-08 |
AU2004218468A1 (en) | 2004-09-16 |
JP2006519181A (en) | 2006-08-24 |
EP2123252B1 (en) | 2017-07-05 |
WO2004078117A3 (en) | 2005-12-22 |
AU2004218468B2 (en) | 2007-04-19 |
US7790768B2 (en) | 2010-09-07 |
US20040171693A1 (en) | 2004-09-02 |
WO2004078117A2 (en) | 2004-09-16 |
EP1599169A2 (en) | 2005-11-30 |
US20100137238A1 (en) | 2010-06-03 |
EP1599169A4 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4709739B2 (en) | How to improve hair growth | |
US9408795B2 (en) | Method for enhancing the growth and fullness of hair | |
BR9712648B1 (en) | composition comprising at least two compounds selected from anti-radical, anti-inflammatory and antiallergic. | |
JP2007526297A (en) | Compositions for modulating hair follicle tropism and sebum skin formation and their use in androgenic alopecia | |
BR0307126B1 (en) | Use of purslane to treat facial wrinkles | |
EP2255782A1 (en) | Composition for the prevention or treatment of hair loss, and method of preparation | |
EP3091961A1 (en) | Exfoliative hair retention-promoting formulation | |
WO2002064088A2 (en) | Pharmaceutical composition for the treatment of alopecia | |
JPH07238007A (en) | Method for preventing hair from falling down and stimulating growing of new hair | |
CN113633585A (en) | External hair care composition and preparation with effects of preventing alopecia, growing hair and blackening hair and preparation method thereof | |
US11045510B2 (en) | Combination of aqueous extracts of watercress and nasturtium and ATP for use in the treatment of alopecia | |
EP3568131B1 (en) | Composition comprising 7-hydroxymatairesinol for use in the treatment and in the prevention of trichological diseases of inflammatory and/or hormonal origin | |
EP1317239B1 (en) | Synergetic combinations based on plants for treating hair loss | |
EP1900356A1 (en) | Extract of fenugreek | |
KR102013871B1 (en) | Composition for improving hair growth | |
CN117255675A (en) | Hair essence and supplement | |
US20240408163A1 (en) | Capillary nutritional complex | |
WO2022094683A1 (en) | Topical-use cosmeceutical composition for stimulating hair growth and for follicle reactivation, method for obtaining, and use | |
JP2009298789A (en) | Use of lepechinia caulescens extract as cosmetic agent and cosmetic composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091022 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100617 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4709739 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |